1. Pink Sheet

Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up

 
• By Neena Brizmohun

Approval applications for nine products received a positive opinion this week from the European Medicines Agency’s drug evaluation committee, the CHMP, and one product was turned down.

3d render of Europe map Earth globe
Nine new products have been recommended for approval across the EU

Novartis and Amgen’s first-of-its-kind migraine drug, Aimovig (erenumab), and Akcea Therapeutics’ new treatment for patients with hereditary transthyretin amyloidosis, Tegsedi (inotersen), are among nine products that the European Medicines Agency this week recommended for approval across the EU.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.